Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014

Fleming, S., Yannakou, C. K., Haeusler, G. M., Clark, J., Grigg, A., Heath, C. H., Bajel, A., van Hal, S. J., Chen, S. C., Milliken, S. T., Morrissey, C. O., Tam, C. S., Szer, J., Weinkove, R. and Slavin, M. A. (2014) Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014. Internal Medicine Journal, 44 12: 1283-1297. doi:10.1111/imj.12595


Author Fleming, S.
Yannakou, C. K.
Haeusler, G. M.
Clark, J.
Grigg, A.
Heath, C. H.
Bajel, A.
van Hal, S. J.
Chen, S. C.
Milliken, S. T.
Morrissey, C. O.
Tam, C. S.
Szer, J.
Weinkove, R.
Slavin, M. A.
Title Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014
Journal name Internal Medicine Journal   Check publisher's open access policy
ISSN 1445-5994
1444-0903
Publication date 2014-12-01
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1111/imj.12595
Open Access Status Not Open Access
Volume 44
Issue 12
Start page 1283
End page 1297
Total pages 15
Place of publication Richmond, VIC Australia
Publisher Wiley-Blackwell Publishing Asia
Language eng
Abstract There is a strong argument for the use of antifungal prophylaxis in high-risk patients given the significant mortality associated with invasive fungal disease, the late identification of these infections, and the availability of safe and well-tolerated prophylactic medications. Clinical decisions about which patients should receive prophylaxis and choice of antifungal agent should be guided by risk stratification, knowledge of local fungal epidemiology, the efficacy and tolerability profile of available agents, and estimates such as number needed to treat and number needed to harm. There have been substantial changes in practice since the 2008 guidelines were published. These include the availability of new medications and/or formulations, and a focus on refining and simplifying patient risk stratification. Used in context, these guidelines aim to assist clinicians in providing optimal preventive care to this vulnerable patient demographic.
Keyword Antifungal prophylaxis
Aspergillus
Candida
Stem cell transplantation
Haematological malignancy
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 14 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 13 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 11 Dec 2015, 19:19:51 EST by System User on behalf of School of Medicine